`
` Notice of Stipulation to Extend Due Date 2
`
`IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
`___________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`___________________
`
`APOTEX, INC.
`Petitioner,
`v.
`UCB BIOPHARMA SPRL
`Patent Owner.
`U.S. Patent No. 8,633,194 to Fanara et al.
`Issue Date: January 21, 2014
`Title: Pharmaceutical Composition of Piperazine Derivatives
`Inter Partes Review No.: IPR2019-00400
`
`Notice of Stipulation to Extend Due Date 2
`
`Mail Stop “PATENT BOARD”
`Patent Trial and Appeal Board
`U.S. Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`
`
`IPR2019-00400
`
` Notice of Stipulation to Extend Due Date 2
`
`Pursuant to the October 7, 2019 Scheduling Order (Paper 21), Petitioner
`
`hereby provides notice that Petitioner and Patent Owner have stipulated and agreed
`
`to extend Due Date 2 as shown below:
`
`Due Date
`DUE DATE 2
`Petitioner’s reply to Patent Owner’s
`response to the petition
`Petitioner’s opposition to Patent
`Owner’s motion to amend
`
`DATED: 1/10/2020
`
`Counsel of Record in IPR 2019-00400
`
`Katten Muchin Rosenman LLP
`/Jitendra Malik /
`Jitendra Malik, Ph.D.
`Reg. No. 55,823
`Counsel for Petitioner Apotex Inc.
`
`Current Date
`January 14, 2020
`
`Revised Date
`January 16, 2020
`
`Fenwick & West LLP
`/Robert E. Counihan/
`Robert E. Counihan
`Reg. No. 61,382
`Counsel
`for Patent Owner UCB
`Biopharma Sprl
`
`